Malachy Asuku currently serves as the Medical Director of Wound Reconstruction & Care, Tissue Technologies at Integra LifeSciences, a global leader in medical technology headquartered in Princeton, New Jersey. He is based in Pennsylvania, United States. Integra, founded in 1989, specializes in innovative medical devices with a focus on surgical, neurologic, and regenerative care.
Dr. Asuku brings decades of clinical, teaching, and research experience as a Plastic and Reconstructive Surgeon. His professional qualifications include MD, FACS (Fellow of the American College of Surgeons), and MBA, reflecting a dual expertise in clinical medicine and business management. He is also recognized academically as a professor of Plastic and Reconstructive Surgery, where he is dedicated to patient care, medical education, and clinical research.
His research portfolio comprises over 45 peer-reviewed journal publications and 28 documented publications with 86 citations, focusing on topics including wound healing, skin grafting techniques, and reconstructive surgery. Notable contributions include studies on the efficacy of Integra Bilayer Wound Matrix for soft tissue reconstruction and the use of Integra’s Dermal Reconstruction Template for complex congenital nevi treatment. His work is referenced in clinical reviews and has been featured in literature addressing infectious complications associated with Integra-based wound closure.
Dr. Asuku is actively involved in the academic community as an editorial adviser and reviewer for journals such as the Journal of Clinical and Diagnostic Research (JCDR). He has also delivered guest lectures and served as an associate editor, demonstrating recognized thought leadership in medical affairs and reconstructive surgery.
Though his leadership role at Integra does not appear in the company’s latest executive leadership press releases or corporate leadership web pages, his position as Medical Director signifies responsibility for advancing innovative wound reconstruction technologies within the Tissue Technologies division, aligning closely with Integra’s corporate mission to innovate treatment pathways and enhance patient outcomes.
Integra LifeSciences, under recent leadership changes including the appointment of Mojdeh Poul as President and CEO (effective January 2025), continues to expand its market presence, reporting first quarter 2025 revenues of $382.7 million (an increase of 3.7% year-over-year on a reported basis). The company was also named a Top 100 Leader in Healthcare Technology for 2024. While Dr. Asuku’s individual contributions to recent company announcements or financial disclosures are not specified, his role as Medical Director places him at the intersection of clinical innovation and product development critical to Integra’s ongoing growth and clinical excellence.
Key professional highlights for sales and partnership insights:
- Current role: Medical Director, Wound Reconstruction & Care, Tissue Technologies at Integra LifeSciences.
- Educational and professional credentials: MD, MBA, FACS, with a longstanding academic appointment in Plastic and Reconstructive Surgery.
- Clinical and research expertise: Extensive background in surgical wound reconstruction and care, with numerous peer-reviewed publications related to Integra’s core product lines.
- Research focus: Wound healing, split-thickness skin graft evaluation, and reconstructive surgical techniques employing Integra’s artificial skin technologies.
- Professional engagement: Active editorial reviewer and invited lecturer, underscoring influence and respect within the medical and surgical communities.
- Geographical base: Pennsylvania, USA, facilitating coordination with Integra’s Princeton headquarters.
Collectively, these elements position Dr. Asuku as a pivotal figure within Integra LifeSciences’ Tissue Technologies sector, driving clinical validation and innovation that support the company’s strategic aims in regenerative medicine and advanced wound care.
